The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Antibody-Drug Conjugates (ADCs) leverage monoclonal antibodies and cytotoxic payloads for targeted cancer therapy.
• Drug resistance, including target antigen alterations and impaired cell death, is a significant challenge for ADCs in oncology.
• ADCs are emerging as a therapeutic strategy for autoimmune diseases, but face hurdles like long-term safety, immunogenicity, and target cell heterogeneity.

Purpose of the Study:

• To review the current landscape of Antibody-Drug Conjugates (ADCs) in cancer and autoimmune disease therapy.
• To identify key challenges hindering ADC efficacy and safety.
• To explore innovative strategies for advancing ADC development.

Main Methods:

• Literature review of Antibody-Drug Conjugate (ADC) applications and challenges.
• Analysis of resistance mechanisms in cancer therapy.
• Examination of emerging ADC therapies for autoimmune diseases.
• Discussion of future directions including molecular design, combination therapies, and AI-assisted development.

Main Results:

• ADCs have demonstrated success in cancer but are hampered by drug resistance mechanisms.
• Emerging ADC therapies for autoimmune diseases present unique safety and efficacy challenges.
• Multidimensional innovations are crucial for overcoming current ADC limitations.

Conclusions:

• Addressing drug resistance and safety concerns is paramount for maximizing ADC therapeutic potential.
• Optimizing molecular design, combination strategies, and AI integration are vital for future ADC development.
• The evolution of ADCs towards intelligent, personalized precision delivery systems promises expanded therapeutic options for cancer and autoimmune diseases.